Vascular Biogenics' Ovarian Cancer Gene Therapy Shows Response Rate Of Over 58%

  • Vascular Biogenics Ltd (NASDAQ: VBLTannounced positive results of the pre-specified interim analysis of the Phase 3 OVAL study of VB-111 (ofranergene obadenovec) in recurrent platinum-resistant ovarian cancer.
  • VB-111 (ofranergene obadenovec) is an anti-cancer gene-therapy.
  • The data was published online in Gynecologic Oncology.
  • The analysis showed a CA-125 (validated biomarker) response rate of 58% or higher in evaluable patients in the VB-111 treatment arm.
  • In patients who had a post-dosing fever, a marker for VB-111 treatment, the response rate was 69%.
  • Recently an independent Data Safety Monitoring Committee found no safety issues with the Phase 3 trial and recommended its continuation.
  • Price Action: VBLT shares are trading higher by 7.6% at $1.98 in premarket trading on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareFDAGeneralOvarian CancerPhase 3
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!